Floatz logo

5-fluoro-2-deoxycytidine

Head and Neck Neoplasms

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Head and Neck Neoplasms cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Pembrolizumab
Mayo Clinic
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4B
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3B

View all 44 →

Same molecule, other indications

5-fluoro-2-deoxycytidine is also rated in:

urinary bladder neoplasmDormant
B
Indicative ·
59 / 100
View asset →
lung neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
breast neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →